Search clinical trials for: Monoclonal antibodies

Total 3760 results

Changchun BCHT Biotechnology Co.
The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaborators

Not yet recruiting

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation

Clostridium Tetanus
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC

Colorectal Cancer | Multiple Cancer

China
Eben Rosenthal
National Cancer Institute (NCI)

Recruiting

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Pancreatic Adenocarcinoma

United States
Stanford University
National Cancer Institute (NCI)

Terminated

Ipilimumab and Local Radiation for Selected Solid Tumors

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
AbbVie

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Korea, Republic of, Taiwan, Israel, Switzerland, United Kingdom, Puerto Rico
AstraZeneca
Amgen

Active, not recruiting

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma (DIRECTION)

Asthma

Korea, Republic of, Philippines, China
Washington University School of Medicine
Hoffmann-La Roche; Genentech, Inc.; National Institute on Aging (NIA); Alzheimer...

Suspended

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, France, Spain, Ireland, Argentina, Australia, Colombia, Germany, Mexico, Netherlands, Puerto Rico, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

Healthy Volunteer

United States
AbbVie

Completed

A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

Healthy Volunteers

China
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Advanced Solid Tumor Malignancies

United States
Tracon Pharmaceuticals Inc.

Completed

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States
Novartis Pharmaceuticals

Completed

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (MEASURE 3)

Spondylitis, Ankylosing

Germany, Spain, United Kingdom, United States, Belgium, Greece, Portugal, Russian Federation, Czechia, Mexico
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Solid Tumors
Merck KGaA, Darmstadt, Germany

Terminated

Raptiva in Palm and Sole Psoriasis

Chronic Plaque Psoriasis
GlaxoSmithKline

Completed

HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

Lymphoma, Follicular

United Kingdom
Biosynexus Incorporated

Completed

Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants

Staphylococcal Sepsis

United States
Celltrion

Recruiting

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps

Rheumatoid Arthritis | Psoriasis | Psoriatic Arthritis | Ankylosing Spondylitis

France
Ultragenyx Pharmaceutical Inc
Novartis; Mereo BioPharma

Withdrawn

Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease

Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Novartis Pharmaceuticals

Completed

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis (SKIPPAIN)

Spondyloarthritis

Belgium, Croatia, Switzerland, Spain, Greece, United Kingdom, Bulgaria, Latvia, Lithuania, Estonia, Italy, Poland, Czechia, Sweden, Russian Federation, Ireland, Finland
Boehringer Ingelheim

Completed

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

Psoriasis

United States, Canada, Finland, France, Germany, Norway, Sweden
Amgen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Crohn's Disease | Ulcerative Colitis

United States, Australia
McGill University
McGill University Health Centre/Research Institute of the McGill University...

Unknown

Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma (Zevalin)

Non-Hodgkin's Lymphoma

Canada
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Wilms Tumor and Other Childhood Kidney Tumors | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Neuroectodermal Tumor and other conditions

United States, Canada, Australia
Peking University Cancer Hospital & Institute

Not yet recruiting

Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis

Melanoma Stage IV
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (BASKETⅡ)

Colorectal Cancer | Immunotherapy

China
NCIC Clinical Trials Group
Merck Frosst Canada Ltd.

Completed

MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Canada
Ludwig Institute for Cancer Research
Pfizer; Heidelberg Pharma AG

Terminated

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma (RCC)

Australia
Philogen S.p.A.

Terminated

Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients

Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection

Italy, Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

Gastric Cancer | Diffuse Type Carcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Breast Cancer | Pancreatic Cancer | Lung Cancer | Rectal Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Colon Cancer | Gastrointestinal Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Thyroid Gland Medullary Carcinoma | Liver and Intrahepatic Biliary Tract Cancer

United States
Shanghai Henlius Biotech

Completed

Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD

Age Related Macular Degeneration

China
Fudan University

Recruiting

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Cancer of Unknown Primary

China
Centocor, Inc.

Completed

An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease

Crohn Disease
Crucell Holland BV

Completed

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Rabies

India
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome (TWINSS Extn)

Sjogren's Syndrome

United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, United States, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Canada, Colombia, Romania, Argentina, Chile, Brazil, S...
AbbVie

Completed

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint)

Psoriasis

United States, Canada, Puerto Rico, Spain
Hoffmann-La Roche

Completed

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Malignant Melanoma

United States, Australia, Brazil, Spain, South Africa, Ukraine, Bosnia and Herzegovina
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
AstraZeneca
MedImmune LLC

Completed

Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus

Japan
Novartis Pharmaceuticals

Completed

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Estonia, France, Canada
Janssen Research & Development, LLC
GlaxoSmithKline

Completed

A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)

Arthritis, Rheumatoid

United States, Poland, Ukraine, Taiwan, Mexico, Bulgaria, Malaysia, Romania, Serbia, South Africa, Korea, Republic of, Japan, Canada, Russian Federation, Chile, Lithuania, Colombia, Croatia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)

Plaque-type Psoriasis

United States, Austria, Germany, France, Japan, Canada, Slovakia, India
Bayer

Completed

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Non-Hodgkin's Lymphoma | Lymphoma, Low-Grade

Japan
Changchun BCHT Biotechnology Co.
The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaborators

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

Rabies Virus Infection

China
Fate Therapeutics

Terminated

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Metastatic Squamous Neck Cancer With Occult Primary | Small Intestine Lymphoma | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Gastrointestinal Stromal Tumor | Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Tongue Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer and other conditions

United States
National Cancer Institute (NCI)

Completed

IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

United States

Search clinical trials for: Monoclonal antibodies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations